Molecular cancer therapeutics
ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin.
Misty D Shields, Katherine G Minton, Hilal Ozakinci, Tianhao Zhou, Olivia C Terry, Paresh Kumar, Reem Akel, Luc Girard, John D Minna, Theresa A Boyle, John M Koomen, Michael Shafique
Published: 202610.1158/1535-7163.MCT-25-0663
Abstract
Small cell lung cancer (SCLC) is a recalcitrant thoracic malignancy known for acquired chemoresistance, early metastatic spread, and poor overall survival. Lurbinectedin, a DNA minor groove alkylating agent, provides durable efficacy in a minority. P…
Preview only. Read the full abstract at the source